Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ERYPAR

ERYTHROMYCIN STEARATE

Standard Dose
EQ 250MG BASE
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview ERYPAR is listed in Drugs@FDA under application 062322 (ANDA).

Marketing status: Discontinued Active ingredient ERYTHROMYCIN STEARATE Form and strength TABLET;ORAL - EQ 250MG BASE Sponsor WARNER CHILCOTT Submission history See approval history documents.

Structured Monograph

Clinical summary

Approval overview ERYPAR is listed in Drugs@FDA under application 062322 (ANDA). Marketing status: Discontinued Active ingredient ERYTHROMYCIN STEARATE Form and strength TABLET;ORAL - EQ 250MG BASE Sponsor WARNER CHILCOTT Submission history See approval history documents.

Monitoring

  • • Review priority: STANDARD
  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.